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INTRODUCTION

Finding participants for secondary prevention of Alzheimer's Disease
Finding participants for Alzheimer's Disease (AD) trials is challenging [1] . This is particularly the case for studies with prodromal or preclinical AD participants, because these persons may not seek care for their problems and are unaware of the presence of amyloid pathology. An increasing number of AD trials aims to delay the onset of dementia in prodromal and preclinical AD. Traditional ad-hoc recruitment strategies, such as advertising in newspapers, result in a costly, labour-intensive and long recruitment process with many screen failures. Novel pre-selection and patient recruitment strategies are warranted. Online registries or the use of existing data sources may help to facilitate recruitment [2] . EPAD Registry makes use of existing data sources for recruitment in a virtual registry in order to speed up recruitment , reduce recruitment efforts, and reduce screen failures.
EPAD Registry as part of the EPAD project
The EPAD Registry is part of the European Prevention of Alzheimer's Dementia (IMI-EPAD) project.
This project is meant to create a platform for AD secondary prevention trials and to improve the understanding of the development of AD, by setting up the EPAD Registry, EPAD longitudinal cohort study (EPAD-LCS) and EPAD proof-of-concept trials (EPAD-PoC) [3] . The EPAD Registry was set-up to find participants without dementia for the EPAD-LCS. In the EPAD-LCS participants undergo longitudinal assessments of cerebral spinal fluid (CSF), blood, MRI, AD risk factors and cognition. The primary outcome is the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The EPAD-LCS serves as the trial readiness cohort for EPAD-PoCs. The first EPAD-PoC is planned to start in 2018.
The EPAD Registry preselects participants from ongoing cohort studies and uses data from these cohorts for prescreening. The EPAD Registry involves several steps (figure 1). First the collaboration with an ongoing cohort study representative is established. Second a minimal dataset from the ongoing cohort study is created that can be queried in a software tool, called PREPAD. Potential participants are identified and invited for the EPAD-LCS by the EPAD study team. The results of these efforts are monitored.
METHODS
Selection of and engagement with ongoing cohort studies
Cohorts that are selected for the EPAD Registry fulfil the following criteria: they are willing to provide participants for the EPAD-LCS, include participants without dementia over the age of 50, collected data suitable for prescreening, and have consent to contact their participants about the EPAD-LCS. In return the ongoing cohort studies will receive the data collected within the EPAD project for their participants. When interest is expressed by a cohort representative, cohort characteristics are collected online either in the European Medical Information Framework (EMIF) or Dementia Platform UK (DPUK) catalogues [4, 5] . Legal contracts are developed to cover interactions between cohorts and EPAD. These contracts cover the use of the virtual registry for EPAD purposes and receiving the EPAD data of their own participants.
Minimal dataset and PREPAD query platform
Each cohort is asked to provide a minimal dataset of variables that can be used to preselect participants with an increased risk for AD. The variables comprise age, gender, education, The minimal dataset is uploaded on a regular basis to the PREPAD software tool. PREPAD was developed to search these minimal datasets. It was adapted from an existing data discovery platform to allow for querying federated datasets and allow complex queries [6] . To ensure participants remain anonymous in the EPAD Registry, a software called 'Deridiom' was created that generates 'Derivative IDs' (derIDs). Deridiom converts cohort local identification numbers to derIDs.
Searching participants with PREPAD involves a number of steps. First an algorithm is defined that aims to identify participants, according to the needs of the EPAD-LCS and EPAD-PoC. The algorithm is tailored for each cohort allowing selection of participants in different risk-stages for AD. An algorithm can for example be a decreased memory score and age over 65. The search results in a list of derIDs.
This list is provided to a cohort representative who converts derIDs into local IDs and selects participants to invite for EPAD-LCS screening.
From EPAD Registry to EPAD-LCS and measuring recruitment rate
After participants have been selected via PREPAD, cohort representatives use local additional prescreening information to decide whether a participant should be invited for EPAD-LCS screening.
Next, a cohort representative approaches a potential participant. Dependent on local preferences and legislation, an opt-in letter is sent or a phone call is made to invite participants to one of the EPAD centres where screening activities and EPAD-LCS procedures will be conducted by the EPAD-LCS team. During the first contact by EPAD with a potential participant, usually by phone, in-and exclusion criteria are checked, such as the availability of a study partner. At each step, summary counts are collected of the number of participants in the process and predefined reasons for prescreen failure such as contra-indication, no contact possible, in other study, unspecified reason, no interest of the participant, and prefer to invite later.
RESULTS
Cohorts
Twenty cohorts representatives from 8 countries completed the first step, the questionnaire about cohort characteristics, each of them giving access to 100 to 500,000 potential participants. Ten cohorts from France, Italy, the Netherlands, Sweden, Spain, Switzerland and the UK are currently formally signed-up to PREPAD, providing access to 17,500 potential participants aged over 50 and without dementia [7] [8] [9] [10] [11] [12] [13] . Incentives for cohorts to participate were: acquiring follow-up and biomarker measures in a subset of the cohort, scientific involvement in EPAD project, and providing clinical trial access for participants. In Table 1a the distribution according to diagnosis and age is presented. The variables available in each of the cohorts are shown in Table 1b . Memory clinic cohorts often have amyloid data available, and almost all cohorts have information on the APOE ε4 status. All cohorts have at least one parameter on cognitive status.
Recruitment for EPAD-LCS via EPAD Registry
As of the first of June 2017, 2433 participants of the EPAD Registry were pre-selected, of whom 75% were invited for EPAD-LCS screening by the team of the collaborating cohorts. The main reason for not contacting a participant was a known exclusion criterion. Most cohorts chose to contact participants by phone. Thus far around 15% of the subjects selected were suitable and agreed to undergo EPAD-LCS screening. This percentage may increase as more of the participants in the EPAD Registry will be considered for EPAD-LCS screening. Reasons of potential participants not entering EPAD-LCS screening are variable and partly dependent on collaborating cohort type. We will monitor uptake prospectively and report on this in detail once we have sufficient data available.
DISCUSSION
The EPAD Registry provides a novel recruitment strategy. It is sufficiently flexible as we can adapt the screening algorithms to the type of data collected in a cohort and the type of participants needed for future EPAD-PoCs.
The collaborating cohorts have different levels of information and draw on different populations. We chose not to define strict criteria for collaboration, but instead to use the data that are available within the cohorts. This approach leads to collaboration with more cohorts than would have been possible otherwise. However, a limitation is that risk estimates vary over cohorts. The efficacy of the approach will be monitored and reported on in the future. This includes the recruitment rate and the characteristics of population recruited, which can then be compared to other strategies. It may well be that this approach is particularly effective for specific populations of volunteers of patients. The adaptation of existing software led to a fast implementation. Plans for further development of the EPAD Registry functions entail extending PREPAD with other risk factors and inclusion of information on exclusion criteria. We also intend further automatization of the harmonization process.
Our approach for recruitment and prescreening differs from those used in other studies and trials aimed at preventing disease progression in preclinical AD. Examples are the Early trial with a BACEinhibitor from Janssen and another BACE inhibitor trial, the A4 study, that stepwise screen individuals from over 65 years old found via advertisements or a website. Additionally for the Early trial, persons between 60 and 64 that have an additional risk factor, being a positive family history for AD or being an APOE ε4 gene carrier can be screened [14, 15] . The API-APOE4 trial from the Banner Institute pioneers with APOE genotyping as a screening method to find suitable trial participants [16] . The MOPEAD project is set up to formally test different recruitment and pre-screening strategies, including an online memory screening and recruitment via a diabetes mellitus outpatient clinic [17] .
Another approach is to let potential participants register online individually. Registrants provide prescreening information, after which the platform matches them to ongoing studies. The Brain Health Registry is a leading example of this. All studies mentioned are ongoing and have not reported yet on the recruitment and the screen failure rate. When the EPAD-PoCs have started, the EPAD Registry approach can be evaluated in terms of trial participation. Combining insights from these various approaches has the potential to greatly improve our understanding of the best ways to find participants for preclinical AD trials in the near future. Our approach could be adapted for other projects in the AD field and beyond, or to find participants within projects, if a minimal dataset for prescreening is available.
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HIGHLIGHTS
• The EPAD Registry approach is aimed at facilitating AD prevention trial recruitment.
• Data of existing cohorts is reused for prescreening purposes.
• Recording the process can help to improve recruitment strategy in the future.
